Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance

被引：11

作者：

Yang-Kolodji, Gloria ^{[1
]}

Mumenthaler, Shannon M. ^{[2
]}

Mehta, Arjun ^{[1
]}

Ji, Lingyun ^{[3
]}

Tripathy, Debu ^{[1
,4
]}

机构：

[1] Univ So Calif, Dept Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA

[2] Univ So Calif, Ctr Appl Mol Med, Los Angeles, CA 90033 USA

[3] Univ So Calif, Dept Prevent Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA

[4] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX USA

来源：

BIOMARKERS | 2015年 / 20卷 / 05期

关键词：

Biomarker; breast cancer; cell model; drug response; trastuzumab resistance; METASTATIC BREAST-CANCER; OVERCOMING RESISTANCE; PARADIGM-SHIFT; SINGLE-AGENT; TRASTUZUMAB; LAPATINIB; SURVIVAL; EFFICACY; SAFETY; KI67;

D O I：

10.3109/1354750X.2015.1068865

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Objective: To identify clinically relevant predictive biomarkers of trastuzumab resistance. Material and methods: MTT, FACS assays, immunoblotting and immunocytochemistry were used to phenotypically characterize drug responses of two cell models BT474R and SKBR3R. Student's t-test and Spearman's correlation were applied for statistic analysis. Results: The activity of a downstream effector of the HER2 pathway phosphorylated ribosomal protein S6 (p-rpS6), was suppressed by trastuzumab in the parental cell lines yet remained unchanged in the resistant cells following treatment. The level of p-rpS6 was inversely correlated to the drug induced growth inhibition of trastuzumab-resistant cells when they are treated with selected HER2 targeting drugs. Conclusion: p-rpS6 is a robust post-treatment indicator of HER2 pathway-targeted therapy resistance.

引用

页码：313 / 322

页数：10

共 47 条

[41] Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer [J].

Sharial, M. S. N. Mohd ;

Crown, J. ;

Hennessy, B. T. .

ANNALS OF ONCOLOGY, 2012, 23 (12) :3007-3016

[42] STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER [J].

SLAMON, DJ ;

GODOLPHIN, W ;

JONES, LA ;

HOLT, JA ;

WONG, SG ;

KEITH, DE ;

LEVIN, WJ ;

STUART, SG ;

UDOVE, J ;

ULLRICH, A ;

PRESS, MF .

SCIENCE, 1989, 244 (4905) :707-712

[43] HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].

SLAMON, DJ ;

CLARK, GM ;

WONG, SG ;

LEVIN, WJ ;

ULLRICH, A ;

MCGUIRE, WL .

SCIENCE, 1987, 235 (4785) :177-182

[44] Biomarker-Driven Early Clinical Trials in Oncology A Paradigm Shift in Drug Development [J].

Tan, Daniel S. W. ;

Thomas, George V. ;

Garrett, Michelle D. ;

Banerji, Udai ;

de Bono, Johann S. ;

Kaye, Stan B. ;

Workman, Paul .

CANCER JOURNAL, 2009, 15 (05) :406-420

[45]

Tripathy Debu, 2009, F1000 Med Rep, V1, DOI 10.3410/M1-20

[46] Prognostic value of proliferation in invasive breast cancer: a review [J].

van Diest, PJ ;

van der Wall, E ;

Baak, JPA .

JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (07) :675-681

[47] Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer [J].

Vogel, CL ;

Cobleigh, MA ;

Tripathy, D ;

Gutheil, JC ;

Harris, LN ;

Fehrenbacher, L ;

Slamon, DJ ;

Murphy, M ;

Novotny, WF ;

Burchmore, M ;

Shak, S ;

Stewart, SJ ;

Press, M .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :719-726

← 1 2 3 4 5 →